1. An activated leukocyte composition for the treatment of wounds, containing: a) from 40% to 90% of granulocytes； b) from 5% to 20% of monocytes； and c) from 5% to 30% of lymphocytes. 2. The composition of claim 1, comprising: a) at least 95% viable leukocytes based on the total number of these leukocyte cells in the activated leukocyte composition； and / or b) at least 75% of CD11b (+) granulocytes, relative to the total population of granulocytes in the activated leukocyte composition. 3. The composition of claim 1, wherein the granulocytes contain: i) from 52% to 78% of neutrophils； ii) from 1% to 9% of eosinophils； and iii) from 1% to 2% of basophils. 4. The composition of claim 1, wherein the lymphocytes contain: i) from 7% to 25% B cells (CD19 +)； ii) from 20% to 30% NK cells (CD3- / CD56 +)； iii) from 40% to 60% T-cells (CD3 +)； iv) from 0% to 30% of tubing cells (CD3 + / CD56 +)； v) from 8% to 20% of T-helper cells, (CD4 + / CD3 +)； iv) from 20% to 30% of CD8 + / CD3 + cells. 5. The composition according to any one of paragraphs. 1-4 for use as a medicine. 6. The composition according to any one of paragraphs. 1-4 for use as an agent for wound healing. 7. The use of an activated leukocyte composition according to any one of paragraphs. 1-4 in the manufacture of a medicament for treating wounds. 8. The use according to claim 7, wherein the wound is a decubital ulcer, pressure sore ulcer, ulcer of the lower extremity of a diabetic patient, a deep sternum wound, a postoperative wound, a refractory postoperative wound of the trunk region, a saphenous vein wound after selection of a large saphenous vein, a wound resulting from an injury anal fissure or venous ulcer. 9. Dressing for the treatment of wounds containing a composition according to any one of paragraphs. 1-4.10. Physiologically inert and / or absorbable matrix or framework containing the composition according to any one of paragraphs. 1-4.1. Активированная лейкоцитарная композиция для лечения ран, сод
